These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27581642)

  • 21. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
    Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.
    Noguchi-Yachide T; Sakai T; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2015 Mar; 23(5):953-9. PubMed ID: 25678016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
    Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
    Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
    Wollebo HS; Bellizzi A; Cossari DH; Salkind J; Safak M; White MK
    J Neurovirol; 2016 Oct; 22(5):615-625. PubMed ID: 27007123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
    Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
    Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
    Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
    Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET inhibition as a new strategy for the treatment of gastric cancer.
    Montenegro RC; Clark PG; Howarth A; Wan X; Ceroni A; Siejka P; Nunez-Alonso GA; Monteiro O; Rogers C; Gamble V; Burbano R; Brennan PE; Tallant C; Ebner D; Fedorov O; O'Neill E; Knapp S; Dixon D; Müller S
    Oncotarget; 2016 Jul; 7(28):43997-44012. PubMed ID: 27259267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor.
    Endo J; Hikawa H; Hamada M; Ishibuchi S; Fujie N; Sugiyama N; Tanaka M; Kobayashi H; Sugahara K; Oshita K; Iwata K; Ooike S; Murata M; Sumichika H; Chiba K; Adachi K
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1365-70. PubMed ID: 26869194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
    Baud MG; Lin-Shiao E; Zengerle M; Tallant C; Ciulli A
    J Med Chem; 2016 Feb; 59(4):1492-500. PubMed ID: 26367539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of methyl isoxazoleazepines as inhibitors of BET.
    Hewitt MC; Leblanc Y; Gehling VS; Vaswani RG; Côté A; Nasveschuk CG; Taylor AM; Harmange JC; Audia JE; Pardo E; Cummings R; Joshi S; Sandy P; Mertz JA; Sims RJ; Bergeron L; Bryant BM; Bellon S; Poy F; Jayaram H; Tang Y; Albrecht BK
    Bioorg Med Chem Lett; 2015 May; 25(9):1842-8. PubMed ID: 25851940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
    Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
    Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRD4: a BET(ter) target for the treatment of AML?
    Valent P; Zuber J
    Cell Cycle; 2014; 13(5):689-90. PubMed ID: 24526121
    [No Abstract]   [Full Text] [Related]  

  • 39. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic regulation of lipoprotein lipase gene via BRD4, which is potentially associated with adipocyte differentiation and insulin resistance.
    Inoue T; Hariya N; Imamochi Y; Dey A; Ozato K; Goda T; Kubota T; Mochizuki K
    Eur J Pharmacol; 2019 Sep; 858():172492. PubMed ID: 31233750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.